Sedivention, a medical technology startup based in Straßlach, Germany, has secured €800,000 in pre-seed funding to advance its innovative obesity treatment device.
With fresh funds, Sedivention intends to accelerate the development of its minimally invasive, one-time interventional therapy aimed at providing an effective solution for individuals struggling with obesity.
The round was led by High-Tech Gründerfonds (HTGF).
Sedivention is developing a medical device that enables a one-time, interventional, and minimally invasive therapy for obesity.
The medical device startup Sedivention is developing a cryocatheter that ablates the gastric branches of the vagus nerve within minutes. The procedure can be performed in an outpatient setting, similar to a gastroscopy, as a one-time, minimally invasive procedure.
A prototype has already been developed and successfully tested for safety and efficacy.